LSBCF (LakeShore Biopharma Co) Loans Receivable: $0.00 Mil (As of Mar. 2025)


What is LakeShore Biopharma Co Loans Receivable?

LakeShore Biopharma Co LSBCF Loans Receivable is $0.00 Mil as of Mar. 2025.

LakeShore Biopharma Co's Loans Receivable for the quarter that ended in Mar. 2025 was $0.00 Mil.

LakeShore Biopharma Co Loans Receivable Related Terms

LakeShore Biopharma Co Loans Receivable Historical Data

* Premium members only.

The historical data trend for LakeShore Biopharma Co's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LakeShore Biopharma Co Loans Receivable Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Loans Receivable
0.46 0.00 0.00 0.00 0.00

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25
Loans Receivable Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

LakeShore Biopharma Co Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
LakeShore Biopharma Co (LSBCF) has a Loans Receivable of $0.00 Mil as of Mar. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on LakeShore Biopharma Co and its competitors.
Is LakeShore Biopharma Co's Loans Receivable too high?
LakeShore Biopharma Co's current Loans Receivable is $0.00 Mil.
How does LakeShore Biopharma Co's Loans Receivable compare to ACUT and PPCB?
LakeShore Biopharma Co's Loans Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current Loans Receivable is $0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LakeShore Biopharma Co Business Description

Address 38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.